Business Context and Reporting Period
Company: Thermo Electron Corporation (now Thermo Fisher Scientific Inc.)
Filing Type: Form 10-K
Reporting Period: Fiscal year ended December 31, 2005
Thermo Electron is a global provider of analytical instruments, scientific equipment, services, and software solutions for life science, drug discovery, clinical, environmental, and industrial laboratories. The company operates through two principal segments: Life and Laboratory Sciences and Measurement and Control. In 2005, the company continued its strategy of driving internal growth and augmenting it with strategic acquisitions, most notably the acquisition of the Kendro Laboratory Products division of SPX Corporation for $836.6 million in May 2005.
Key Financial Metrics
| Metric | 2005 | 2004 |
|---|---|---|
| Revenues | $2,633.0 million | $2,206.0 million |
| Operating Income | $263.5 million | $237.5 million |
| Operating Margin | 10.0% | 10.8% |
| Net Income | $223.2 million | $361.8 million |
| Diluted EPS | $1.36 | $2.17 |
| Cash Flow from Operations | $270.9 million | $264.5 million |
| Total Debt (Outstanding) | $598.8 million | $226.1 million (Long-term only) |
| Working Capital | $562.2 million | $890.9 million |
| Cash and Short-term Investments | $295.0 million | $512.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 19% to $2.633 billion. This was driven primarily by acquisitions (net of divestitures) contributing $337.3 million (15%) and organic growth of 4% due to increased demand. Currency translation had an unfavorable impact of $4.5 million due to a strengthening U.S. dollar.
- Profitability: While operating income increased to $263.5 million, the operating margin declined to 10.0% from 10.8%. This decrease was primarily due to $54.8 million in higher amortization expense related to acquisition-related intangible assets and $10.0 million in higher charges to cost of revenues (inventory revaluations).
- Net Income Decline: Net income decreased significantly to $223.2 million from $361.8 million. This was largely due to the absence of a $33.8 million tax benefit recorded in 2004 from the settlement of tax audits, which had reduced the 2004 effective tax rate to 15.8%. The 2005 effective tax rate was 30.6%.
- Debt and Liquidity: Total outstanding debt increased to $598.8 million, primarily to fund the Kendro acquisition. Working capital decreased to $562.2 million from $890.9 million due to the use of cash and debt for acquisitions.
Guidance, Outlook, Risks, and Unusual Items
- Acquisitions and Integration: The company expects to finalize restructuring plans for the Kendro acquisition within one year, with total charges to expense estimated at $15–$20 million (approximately $8 million recorded as of year-end). The company anticipates realizing cost savings and synergies from this integration.
- Restructuring: The company recorded $30.3 million in restructuring and other costs in 2005, primarily for staffing reductions and facility consolidations. These actions are expected to yield annual cost savings of approximately $13 million.
- Legal Proceedings: The company is involved in patent litigation with Applied Biosystems/MDS Scientific Instruments regarding mass spectrometer systems. An unfavorable outcome could have a material adverse effect on financial results. Additionally, an arbitration proceeding with Chromagen, Inc. is pending.
- Market Risks: The company faces risks related to currency exchange rates (58% of revenues are international), cyclical downturns in industrial markets served by the Measurement and Control segment, and the need to continuously innovate to prevent product obsolescence.
- Accounting Changes: The company will adopt SFAS No. 123(R) in 2006, which is expected to reduce net income by approximately $16 million ($0.10 per diluted share) due to the expensing of stock-based compensation.
Key Facts for Investor Verification
- Acquisition Integration: Verify the progress and cost realization of the Kendro Laboratory Products integration, specifically the remaining $7–$12 million in expected restructuring charges.
- Patent Litigation: Monitor the status of the patent infringement lawsuit with Applied Biosystems/MDS Scientific Instruments and the Chromagen arbitration, as these pose significant contingent liabilities.
- Goodwill Impairment: With goodwill totaling $1.97 billion, verify the company's annual impairment testing results, particularly given the high level of recent acquisitions.
- Debt Covenants: Confirm continued compliance with debt covenants, specifically the Consolidated Interest Coverage Ratio (minimum 3.25:1) and Debt-to-Capitalization ratio (maximum 0.50:1), given the increased leverage.
- Organic Growth: Assess the sustainability of the 4% organic revenue growth excluding acquisitions and currency effects, particularly in the Life and Laboratory Sciences segment.